Enanta Pharmaceuticals

Description

• Enanta Pharmaceuticals is a research and development-focused biotechnology company that uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs for viral infections and liver diseases. Enantas research and development efforts are currently focused on the following disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV). Enanta has discovered novel protease inhibitors for use against the hepatitis C virus (HCV). These protease inhibitors, developed through Enantas collaboration with AbbVie, include paritaprevir, currently marketed in AbbVies HCV regimens, and glecaprevir (ABT-493), Enantas second protease inhibitor product, which AbbVie is developing as part of its investigational HCV regimen of glecaprevir/pibrentasvir (G/P) now in registration in the U.S., the E.U. and Japan. Royalties and any further milestone payments from this collaboration will provide funding for Enantas earlier development programs, including its Phase 1 FXR agonist program for NASH/PBC, and its preclinical programs for HBV and RSV.
• 

  Headquarters:500 Arsenal Street , Watertown, Massachusetts, United States

  More
• 

  Phone Number: +1 617-607-0800

• 

  Website: https://www.enanta.com

• 

  Employees:142

• 

  Revenue:$10 - 50M

• 

  Legal Name:Enanta Pharmaceuticals

• Enanta Pharmaceuticals's Social Media

  
• Is this data correct?

• |  NAICS Code: 325412  |

  Show More